Abstract
The epidemiology, natural history, patient presentation, staging, prognosis, and treatment of colorectal cancer are described. Colorectal cancer is a common malignancy that usually is not diagnosed when it is localized because it typically is asymptomatic in the early stages. Various cancer chemotherapeutic agents with different toxicities are available, including the recently introduced recombinant humanized immunoglobulin G(1) monoclonal antibodies cetuximab and bevacizumab. Chemotherapy may be used with or without surgery in patients with advanced or metastatic colorectal cancer, usually for palliation rather than a cure. The results of clinical trials suggest that patients with advanced or metastatic colorectal cancer probably should receive 5-fluorouracil (5-FU)/leucovorin, irinotecan, oxaliplatin, bevacizumab, and cetuximab at some time in the course of treatment, although the preferred combinations and sequence of these agents remain to be determined. After surgery, adjuvant chemotherapy may be used for curative purposes in patients with stage III disease and some patients with stage II disease at high risk for disease recurrence and death. Although 5-FU plus leucovorin has been the standard adjuvant therapy, clinical tr...Continue Reading
References
Apr 1, 1995·The Journal of Clinical Investigation·R S WarrenN Ferrara
Apr 29, 1993·Nature·K J KimN Ferrara
Jul 28, 1994·The New England Journal of Medicine·J JenS R Hamilton
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J O'ConnellH S Wieand
Apr 14, 1999·CA: a Cancer Journal for Clinicians·D M ParkinJ Ferlay
Feb 25, 2000·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·I PorebskaT Bojarowski
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Sep 5, 2001·Nature Medicine·R K Jain
Oct 13, 2001·The New England Journal of Medicine·D J SargentG Francini
Dec 11, 2002·Journal of Cancer Research and Clinical Oncology·V BazanA Russo
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz KabbinavarEmily Bergsland
Jun 13, 2003·Seminars in Oncology·Nishan H Fernando, Herbert I Hurwitz
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Apr 7, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharlene GillRichard M Goldberg
May 11, 2004·Cancer Chemotherapy and Pharmacology·Gareth J VealAlan V Boddy
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Jun 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Al B BensonDaniel G Haller
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurence GamelinErick Gamelin
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Oct 7, 2004·Journal of the National Cancer Institute·Jessica B O'ConnellClifford Y Ko
Nov 13, 2004·CA: a Cancer Journal for Clinicians·Carolyn C Compton, Frederick L Greene
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarWilliam F Novotny
Apr 28, 2005·Cancer Control : Journal of the Moffitt Cancer Center·Todd Alekshun, Chris Garrett
Jun 9, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Rachel Midgley, David Kerr
Jul 1, 2005·The New England Journal of Medicine·Chris TwelvesWerner Scheithauer
Oct 27, 2005·The Oncologist·Ki Young Chung, Leonard B Saltz